Quantum BioPharma Secures CRO Letter of Intent for Q2 2026 Phase 2 MS Trial
Quantum BioPharma signed a binding letter of intent with Allucent to execute its planned Phase 2 trial of Lucid-MS, a first-in-class demyelination inhibitor, targeting initiation in Q2 2026. Allucent will handle study start-up, global site management, patient recruitment and data integrity for the multiple sclerosis therapy.
1. Binding Letter of Intent Details
Quantum BioPharma entered into a binding letter of intent with Allucent to support the Phase 2 clinical trial of Lucid-MS in multiple sclerosis. The LOI outlines comprehensive CRO services and will be followed by a definitive services agreement in the coming weeks.
2. Planned Phase 2 Trial Timeline and Scope
The Phase 2 trial will evaluate efficacy, safety and tolerability of Lucid-MS in people with multiple sclerosis. Quantum BioPharma plans to initiate the study in Q2 2026, pending regulatory approvals and finalization of trial design and operational arrangements.
3. First-in-Class Mechanism and Market Potential
Lucid-MS is a new chemical entity designed to inhibit demyelination, addressing neurodegeneration directly rather than modulating the immune system. Multiple sclerosis affects around 2.8 million people worldwide, with the global MS therapeutic market projected to exceed $38 billion by 2030.
4. Allucent’s Expertise and Execution Plan
Allucent will provide regulatory submissions, site selection and management, patient recruitment, data management and regulatory support. Its global CNS trial experience and integrated operational model aim to ensure efficient execution and high-quality data integrity throughout the study.